121 related articles for article (PubMed ID: 16951490)
21. Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia.
Gora-Tybor J; Blonski JZ; Robak T
Eur Cytokine Netw; 2005; 16(1):41-6. PubMed ID: 15809205
[TBL] [Abstract][Full Text] [Related]
22. Comparison of angiogenic factor levels in tumor drainage and peripheral venous blood from colorectal cancer patients.
Tien YW; Chang KJ; Chiu YF; Huang KW; Lee PH
Ann Surg Oncol; 2006 Nov; 13(11):1357-63. PubMed ID: 17001510
[TBL] [Abstract][Full Text] [Related]
23. Prognostic importance of soluble CD23 in B-cell chronic lymphocytic leukemia.
Saka B; Aktan M; Sami U; Oner D; Sanem O; Dinçol G
Clin Lab Haematol; 2006 Feb; 28(1):30-5. PubMed ID: 16430457
[TBL] [Abstract][Full Text] [Related]
24. Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia.
Gora-Tybor J; Blonski JZ; Robak T
Neoplasma; 2002; 49(3):145-8. PubMed ID: 12097998
[TBL] [Abstract][Full Text] [Related]
25. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
[TBL] [Abstract][Full Text] [Related]
26. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia.
Lai R; O'Brien S; Maushouri T; Rogers A; Kantarjian H; Keating M; Albitar M
Cancer; 2002 Sep; 95(5):1071-5. PubMed ID: 12209693
[TBL] [Abstract][Full Text] [Related]
28. Elevated serum level of circulating syndecan-1 (CD138) in active systemic lupus erythematosus.
Minowa K; Amano H; Nakano S; Ando S; Watanabe T; Nakiri Y; Amano E; Tokano Y; Morimoto S; Takasaki Y
Autoimmunity; 2011 Aug; 44(5):357-62. PubMed ID: 21320038
[TBL] [Abstract][Full Text] [Related]
29. Soluble CD138 serum levels are not associated with other poor prognostic markers in patients with B-chronic lymphocytic leukaemia.
Alonci A; Allegra A; Bellomo G; D'Angelo A; Penna G; Cannavò A; Musolino C
Med Oncol; 2010 Dec; 27(4):1336-9. PubMed ID: 20013319
[TBL] [Abstract][Full Text] [Related]
30. [Soluble syndecan-1 levels in different plasma cell dyscrasias].
Jánosi J; Sebestyén A; Mikala G; Petö M; Jákó J; Domján G; Németh J; Kis Z; Kopper L; Vályi-Nagy I
Orv Hetil; 2005 Jan; 146(4):165-8. PubMed ID: 15751511
[TBL] [Abstract][Full Text] [Related]
31. FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia.
Nückel H; Collins CH; Frey UH; Sellmann L; Dürig J; Siffert W; Dührsen U
Eur J Haematol; 2009 Dec; 83(6):541-9. PubMed ID: 19682311
[TBL] [Abstract][Full Text] [Related]
32. Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons.
Bauvois B; Dumont J; Mathiot C; Kolb JP
Leukemia; 2002 May; 16(5):791-8. PubMed ID: 11986939
[TBL] [Abstract][Full Text] [Related]
33. Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia.
Molica S; Vitelli G; Levato D; Ricciotti A; Digiesi G
Br J Cancer; 2002 Jan; 86(1):31-5. PubMed ID: 11857008
[TBL] [Abstract][Full Text] [Related]
34. B-chronic lymphocytic leukemia cells exert an in vitro cytotoxicity mediated by tumor necrosis factor alpha.
Rosati E; Sabatini R; Tabilio A; Di Ianni M; Bartoli A; Marconi P
Leuk Res; 2005 Jul; 29(7):829-39. PubMed ID: 15927678
[TBL] [Abstract][Full Text] [Related]
35. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group.
Schips L; Dalpiaz O; Lipsky K; Langner C; Rehak P; Puerstner P; Pummer K; Zigeuner R
Eur Urol; 2007 Jan; 51(1):168-73; discussion 174. PubMed ID: 16844285
[TBL] [Abstract][Full Text] [Related]
36. Angiogenic and coagulation-fibrinolysis factors in non Hodgkin's lymphoma.
Wróbel T; Poreba M; Mazur G; Poreba R; Pyszel A; Beck B; Steinmetz-Beck A; Andrzejak R; Kuliczkowski K
Neoplasma; 2006; 53(3):253-8. PubMed ID: 16652197
[TBL] [Abstract][Full Text] [Related]
37. B-cell chronic lymphocytic leukemia: correlation of clinical stages with angiogenic cytokine expression.
Ho CL; Phyliky RL; Li CY
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):154-60. PubMed ID: 16785782
[TBL] [Abstract][Full Text] [Related]
38. Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma.
Uematsu S; Higashi T; Nouso K; Kariyama K; Nakamura S; Suzuki M; Nakatsukasa H; Kobayashi Y; Hanafusa T; Tsuji T; Shiratori Y
J Gastroenterol Hepatol; 2005 Apr; 20(4):583-8. PubMed ID: 15836707
[TBL] [Abstract][Full Text] [Related]
39. Serum levels of soluble syndecan-1 in Hodgkin's lymphoma.
Vassilakopoulos TP; Kyrtsonis MC; Papadogiannis A; Nadali G; Angelopoulou MK; Tzenou T; Dimopoulou MN; Siakantaris MP; Kontopidou FN; Kalpadakis C; Kokoris SI; Dimitriadou EM; Tsaftaridis P; Pizzolo G; Pangalis GA
Anticancer Res; 2005; 25(6C):4743-6. PubMed ID: 16334170
[TBL] [Abstract][Full Text] [Related]
40. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia.
Ferrajoli A; Manshouri T; Estrov Z; Keating MJ; O'Brien S; Lerner S; Beran M; Kantarjian HM; Freireich EJ; Albitar M
Clin Cancer Res; 2001 Apr; 7(4):795-9. PubMed ID: 11309324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
